Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin.
Urinary hesitancy can be an uncomfortable side effect during antidepressant treatment. Clinicians often use the selective alpha(1A)-adrenoceptor antagonist, tamsulosin, to treat urinary hesitancy associated with prostate enlargement. We report here a series of case studies in which tamsulosin has been successfully used in the management of urinary hesitancy during therapy with the selective noradrenaline reuptake inhibitor reboxetine for major depressive disorder (MDD). Eight male adults (aged 43-64 years; DSM-IV diagnosis of MDD) who were receiving treatment with reboxetine (4-8 mg/day) were considered candidates for concomitant tamsulosin (0.4 mg/day) therapy. Tamsulosin was administered either as prophylaxis (n=4) or as treatment (n=4) for emergent urinary hesitancy. All patients experienced relief of urinary hesitancy within 20 min of tamsulosin therapy and this effect was sustained. Concomitant treatment with tamsulosin should be considered for those patients in whom urinary hesitancy may lead to withdrawal from reboxetine therapy.
Kasper
S
S
Department of General Psychiatry, University of Vienna, Hospital for Psychiatry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. sk@akh-wien.ac.at
Wolf
R
R
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects*; D000077593:Reboxetine; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D016055:Urinary Retention / Q000139:chemically induced* / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000928:Antidepressive Agents; D009025:Morpholines; D013449:Sulfonamides; D000077593:Reboxetine; D000077409:Tamsulosin